Skip to main content
Clinical Trials/NCT02635347
NCT02635347CompletedNot Applicable

Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study

Rutgers, The State University of New Jersey2 sites in 1 country31 target enrollmentStarted: November 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
31
Locations
2
Primary Endpoint
Percentage of Participants Completing Entire Intervention Protocol

Study Overview

Brief Summary

This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT). Remote ischemic conditioning will consist of 3 cycles of 5 minutes of lower limb ischemia induced via a mid-thigh pneumatic tourniquet, followed by 5 minutes of reperfusion. Interventions will take place after anesthesia induction but before surgery, at the completion of the procedure, and on the mornings of post-operative days 1-4.

Detailed Description

Orthotopic liver transplantation (OLT) is associated with a very high risk of complications. In a recent multi-center study of 450 patients, 79% had at least one complication and 63% had severe (Clavien-Dindo grade III or higher) complications. The number and severity of complications are associated with death within 30 days, hospital length of stay, graft and patient survival. Infections are the most common group of complications, followed by pulmonary, renal and liver graft dysfunction. Interventions that decrease these complications after OLT are likely to improve clinical outcomes.

Remote ischemic conditioning is an innate biological phenomenon wherein a brief single or repetitive ischemic stimulus in an organ or tissue such as skeletal muscle induce protection in remote/distant organs against ischemia and other noxious stimuli. This effect can be induced by inflating a pneumatic tourniquet on a leg or arm for a few minutes (usually 5-10) and subsequently deflating to allow reperfusion. This process is usually repeated 3-4 times to ensure an adequate dose of the conditioning stimulus. The conditioning stimulus could be applied before (Preconditioning), concurrent with (Perconditioning), or soon after the index noxious/ischemic insult (Postconditioning).

The goal of this study is to assess the feasibility, patient acceptance, and safety of RIC in liver recipients. In addition, the investigators will obtain data on posttransplant complications. Information obtained from this study will help guide the design of a future randomized, controlled trial to test the benefit of RIC in liver recipients.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults (> 18 years of age) with acute and chronic liver failure requiring liver transplants or patients undergoing transplantation for hepatocellular carcinoma.
  • Both sexes
  • Written consent to participate in the study

Exclusion Criteria

  • < 18 years of age
  • Recipients of split livers
  • Retransplantation
  • Recipients of livers combined with other organs
  • Recipients of livers from cardiac death donors
  • Lower extremity amputees
  • History of peripheral vascular disease
  • Patients taking sulfonylurea anti-diabetic agents at the time of transplant
  • Patients taking nitrates at the time of transplant
  • Body mass index > 45
  • Pregnant patients
  • Patients in whom complete lower extremity ischemia is not achieved despite maximum tourniquet inflation to 250 mmHg during the first intervention
  • Patients with lower extremity paralysis

Arms & Interventions

Remote Ischemic Conditioning (RIC) group

Experimental

Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC

Intervention: Remote Ischemic Conditioning (RIC) (Procedure)

Remote Ischemic Conditioning (RIC) group

Experimental

Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC

Intervention: Pneumatic tourniquet (Device)

Outcomes

Primary Outcomes

Percentage of Participants Completing Entire Intervention Protocol

Time Frame: Pre-op - Post-op day 4

Proportion of enrolled liver recipients that complete all 6 remote ischemic conditioning (RIC) interventions.

Secondary Outcomes

  • Intervention-related Pain Score(Post-op days 1-4)
  • Withdrawal of Consent Due to Pain(Pre-op - Post-op day 7)
  • Percentage of Participants Who Developed Early Allograft Dysfunction (EAD)(Post-op days 0-7)
  • Percentage of Participants Who Developed Prolonged Respiratory Insufficiency (PRI)(Post-op days 0-7)
  • Percentage of Participants Who Developed Acute Kidney Injury (AKI) Stages 2 or 3(Post-op days 0-7)
  • Time to Dialysis Discontinuation(Post-op days 0-90)
  • Presence of Clavien-Dindo Grade IIIb or Higher Complications(Post-op days 0-30)
  • Clavien-Dindo Grade IIIb or Higher - Number of Complications(Post-op days 0-30)
  • Intensive Care Unit (ICU) Length of Stay (LOS)(Post-op days 0 up to 90 days)
  • Number of Subjects Not Completing Intervention Protocol(Pre-op - Post-op day 4)
  • Hospital LOS(Post-op days 0 up to 90 days)
  • Liver Allograft Survival(Post-op day 90)
  • Patient Survival(Post-op day 90)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Baburao Koneru, MD, MPH

Professor, Department of Surgery

Rutgers, The State University of New Jersey

Study Sites (2)

Loading locations...

Similar Trials